Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2017—WaveSense introduced its nRichDX system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRichDX uses the company’s proprietary paramagnetic bead technology to enable the capture of circulating tumor cells and cell-free DNA or cell-free RNA in quantities sufficient for analysis by next-generation sequencing and PCR techniques.
February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world.
February 2017—Qiagen launched the QIAseq cfDNA All-in-One kit, combining cell-free DNA extraction and library preparation in a dedicated solution for liquid biopsy analysis on next-generation sequencing platforms. The kit integrates with Qiagen’s PAXgene Blood ccfDNA tube as well as with the company’s bioinformatics workflow for cfDNA, creating a streamlined testing solution that aims to allow faster, more convenient, and reliable analysis of cell-free DNA from sample collection to interpreted result.
February 2017—Roche launched its Discovery 5-Plex procedure and reagents for immunohistochemistry research applications. This is the first pre-optimized, fully automated multiplex procedure available on the Ventana Discovery Ultra instrument.
February 2017—Meridian Life Science released a new brochure on its best performing tropical and vector-borne antigens and antibodies, including its new Zika reagents. Important troubleshooting tips are included for reducing cross-reactivity in flavivirus assays and increasing IgM detection sensitivity.
February 2017—Applied Spectral Imaging has entered into a collaboration with ARUP Laboratories to facilitate the development and commercialization of advanced digital pathology solutions, enhancing workflow efficiencies and simplifying the management and accessibility of clinical data.
February 2017—PerkinElmer’s Opal Multicolor Immunohistochemistry products for use with Leica Biosystems’ fully automated Bond RX research staining platform is now available. The kits can visualize up to six biomarkers and a nuclear counterstain on a single tissue section with next-day results.
January 2017—Ortho Clinical Diagnostics announced that the Food and Drug Administration has cleared its Vitros Automation Solutions for use with Ortho’s Vitros chemistry, immunodiagnostics, and integrated systems.
January 2017—Qiagen launched its QIAscout, a novel instrument for isolation of viable single cells from samples to enable single-cell analysis for next-generation sequencing, polymerase chain reaction, and other downstream applications.
January 2017—Hardy Diagnostics announced its new product, C Diff Banana Broth, which is recommended as a selective detection broth for the recovery of Clostridium difficile from environmental samples. Its name is derived from the color change reaction when C. diff is present; the broth changes from a deep red, indicating a negative reaction, to a milky yellow, indicating a positive reaction.
